HERV

HERVOLUTION Therapeutics Appoints Biotech Builder J. Robert Coleman as CEO to Accelerate Groundbreaking Immunotherapies to Treat Dark Genome Targets in Cancer, Aging, and Neurodegeneration

Retrieved on: 
Martedì, Dicembre 19, 2023
Immunotherapy, ALS, Neoplasm, Antigen, Immune system, Breast, Multiple sclerosis, Disease, MBA, MD, Doctor of Philosophy, Cancer, HERV, Ageing, Prostate, Infection, Therapy

His skillset is advancing groundbreaking preclinical discoveries into first-in-human proof of concept trials and beyond; thus, Coleman's expertise aligns seamlessly with HERVOLUTION's mission.

Key Points: 
  • His skillset is advancing groundbreaking preclinical discoveries into first-in-human proof of concept trials and beyond; thus, Coleman's expertise aligns seamlessly with HERVOLUTION's mission.
  • The human genomes encode Human Endogenous Retroviral genes (HERVs) that remain as part of the dark genome from retroviral infections of our predecessors.
  • Sven Rohmann, MD, Phd, MBA, Chairman of HERVOLUTION, stated: "We are so delighted to welcome Rob to the HERVOLUTION team.
  • HERVOLUTION is committed to revolutionizing immunotherapy by targeting HERVs as tumor and senescence-specific antigens, antigens that had until now remained elusive for immunotherapy.

HERVOLUTION Therapeutics Appoints Biotech Builder J. Robert Coleman as CEO to Accelerate Groundbreaking Immunotherapies to Treat Dark Genome Targets in Cancer, Aging, and Neurodegeneration

Retrieved on: 
Martedì, Dicembre 19, 2023
Immunotherapy, ALS, Neoplasm, Antigen, Immune system, Breast, Multiple sclerosis, Disease, MBA, MD, Doctor of Philosophy, Cancer, HERV, Ageing, Prostate, Infection, Therapy

His skillset is advancing groundbreaking preclinical discoveries into first-in-human proof of concept trials and beyond; thus, Coleman's expertise aligns seamlessly with HERVOLUTION's mission.

Key Points: 
  • His skillset is advancing groundbreaking preclinical discoveries into first-in-human proof of concept trials and beyond; thus, Coleman's expertise aligns seamlessly with HERVOLUTION's mission.
  • The human genomes encode Human Endogenous Retroviral genes (HERVs) that remain as part of the dark genome from retroviral infections of our predecessors.
  • Sven Rohmann, MD, Phd, MBA, Chairman of HERVOLUTION, stated: "We are so delighted to welcome Rob to the HERVOLUTION team.
  • HERVOLUTION is committed to revolutionizing immunotherapy by targeting HERVs as tumor and senescence-specific antigens, antigens that had until now remained elusive for immunotherapy.

HERVOLUTION Therapeutics appoints Moderna Co-Founder and MIT Professor Robert S. Langer as Chair of its Scientific Advisory Board

Retrieved on: 
Mercoledì, Settembre 13, 2023
SAB, Nobel Prize, DNA, Bevacizumab, National Academy of Medicine, Administration, Biotechnology, National Academy of Sciences, Herv, Cancer, United States Air Force Scientific Advisory Board, National Medal, National Academy of Engineering, Medicine, MIT, RNA, HERV, Regenerative medicine, Blood, Professor, National academy, Anpartsselskab, Tissue engineering, Moderna, Immune system, Novo Nordisk Foundation, ARD International Music Competition, Viral, Drug development, BII, Therapy, Pharmaceutical industry, Vaccine

COPENHAGEN, Denmark, Sept. 13, 2023 /PRNewswire/ -- HERVOLUTION Therapeutics (HERVOLUTION) (formerly InProTher ApS), an early-stage biotechnology company developing effective cancer immunotherapies targeting Human Endogenous Retroviruses (HERVs), today announces the appointment of Professor Robert S. Langer, Sc D., as Chair of its Scientific Advisory Board (SAB).

Key Points: 
  • COPENHAGEN, Denmark, Sept. 13, 2023 /PRNewswire/ -- HERVOLUTION Therapeutics (HERVOLUTION) (formerly InProTher ApS), an early-stage biotechnology company developing effective cancer immunotherapies targeting Human Endogenous Retroviruses (HERVs), today announces the appointment of Professor Robert S. Langer, Sc D., as Chair of its Scientific Advisory Board (SAB).
  • Professor Robert S. Langer, newly appointed Chair of HERVOLUTION's Scientific Advisory Board, commented: "Oncology needs a paradigm shift.
  • Dr Peter Holst, Founder and Chief Scientific Officer of HERVOLUTION, said: "We are honoured to welcome Professor Langer as Chair of HERVOLUTION's Scientific Advisory Board.
  • Prof Langer is the co-founder of Moderna Therapeutics and Professor at the Massachusetts Institute of Technology (MIT).

HERVOLUTION Therapeutics appoints Moderna Co-Founder and MIT Professor Robert S. Langer as Chair of its Scientific Advisory Board

Retrieved on: 
Mercoledì, Settembre 13, 2023
SAB, Nobel Prize, DNA, Bevacizumab, National Academy of Medicine, Administration, Biotechnology, National Academy of Sciences, Herv, Cancer, United States Air Force Scientific Advisory Board, National Medal, National Academy of Engineering, Medicine, MIT, RNA, HERV, Regenerative medicine, Blood, Professor, National academy, Anpartsselskab, Tissue engineering, Moderna, Immune system, Novo Nordisk Foundation, ARD International Music Competition, Viral, Drug development, BII, Therapy, Pharmaceutical industry, Vaccine

COPENHAGEN, Denmark, Sept. 13, 2023 /PRNewswire/ -- HERVOLUTION Therapeutics (HERVOLUTION) (formerly InProTher ApS), an early-stage biotechnology company developing effective cancer immunotherapies targeting Human Endogenous Retroviruses (HERVs), today announces the appointment of Professor Robert S. Langer, Sc D., as Chair of its Scientific Advisory Board (SAB).

Key Points: 
  • COPENHAGEN, Denmark, Sept. 13, 2023 /PRNewswire/ -- HERVOLUTION Therapeutics (HERVOLUTION) (formerly InProTher ApS), an early-stage biotechnology company developing effective cancer immunotherapies targeting Human Endogenous Retroviruses (HERVs), today announces the appointment of Professor Robert S. Langer, Sc D., as Chair of its Scientific Advisory Board (SAB).
  • Professor Robert S. Langer, newly appointed Chair of HERVOLUTION's Scientific Advisory Board, commented: "Oncology needs a paradigm shift.
  • Dr Peter Holst, Founder and Chief Scientific Officer of HERVOLUTION, said: "We are honoured to welcome Professor Langer as Chair of HERVOLUTION's Scientific Advisory Board.
  • Prof Langer is the co-founder of Moderna Therapeutics and Professor at the Massachusetts Institute of Technology (MIT).

Long COVID could be caused by the virus lingering in the body. Here's what the science says

Retrieved on: 
Sabato, Giugno 10, 2023
Inflammation, Infection, Tissue, Heart, Epstein–Barr virus, DNA, Autoantibody, HIV, Vaccination, SARS-CoV-2, Eye, Herve Bostan Amani, Viral, Brain, COVID, Cell, RNA, Antibody, Autoimmunity, HERV, Psoriasis, Thought, Measles, Inflammatory bowel disease, Nose, Viral disease, Herpes virus, Dementia, Protein, Patient, Risk, Infectious mononucleosis, Blood, Immune system, Conditional sentence, Colonoscopy, DSM-IV codes, Autoimmune disease, Area studies, Research, Virus, Autopsy, Fatigue, Pharmaceutical industry, Vaccine, Copper

When symptoms last longer than 12 weeks, the condition is known as long COVID.

Key Points: 
  • When symptoms last longer than 12 weeks, the condition is known as long COVID.
  • Long COVID encompasses up to 200 different symptoms.
  • One factor that may be associated with long COVID is that the virus hasn’t fully cleared from the body after the initial infection.

Other viruses lurk in the body

    • This means the virus conceals itself within cells and remains dormant.
    • HIV, in particular, can remain dormant in infected cells throughout the body.
    • Several studies have shown COVID can also reactivate the Epstein-Barr virus, which has remained in the body in a latent state.

How do we know COVID stays in the body?

    • SARS-CoV-2 RNA was detected in at least half the samples of heart, lymph glands, eye, nerve, brain and lung tissue tested.
    • These patients had asymptomatic COVID and were PCR-negative from swabs of the nose and throat at four months.
    • Initial studies did not always suggest a strong relationship between the long-term detection of SARS-CoV-2 and long COVID symptoms.

How might the delay in clearing the virus impact people with long COVID?

    • We have previously shown immune dysfunction and inflammation persist up to eight months in people with long COVID that initially had mild to moderate disease.
    • Read more:
      When does COVID become long COVID?
    • Antibodies reactive to Epstein-Barr virus are elevated in people with long COVID suggesting Epstein-Barr virus reactivation, likely through activating the immune system.
    • This should include examination of viral RNA and protein in both blood and tissues in people with long COVID independent of disease severity.

InProTher Announces EUR 6M Seed Financing with the Participation of the European Innovation Council Fund to Develop First-In-Class Cancer Immunotherapy

Retrieved on: 
Mercoledì, Maggio 24, 2023
Survival rate, Adenoviridae, European Innovation Council, Herv, Cancer, Venture capital financing, Breast, CMO, RNA, Immunotherapy, Doctor of Philosophy, HERV, Manager, EUR, Koala retrovirus, Novartis, MD, Investment, Immune system, Novo Nordisk Foundation, Drug development, FIH, Growth, Merck, BII, EIC, Seed, MPM, SME, Pharmaceutical industry, Management, Security (finance), EU

The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumors, into clinical development.

Key Points: 
  • The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumors, into clinical development.
  • InProTher has generated robust pre-clinical, proof-of-concept data that demonstrates therapeutic potential for multiple oncology indications including pancreatic, ovarian, breast and prostate cancer.
  • Jordi Naval, Chief Executive Officer of InProTher said: "InProTher is shifting the paradigm in cancer immunotherapy and is at an exciting phase of growth.
  • The Seed round of EUR 6M includes private investors and a convertible loan from EICF.

InProTher Announces EUR 6M Seed Financing with the Participation of the European Innovation Council Fund to Develop First-In-Class Cancer Immunotherapy

Retrieved on: 
Mercoledì, Maggio 24, 2023
Survival rate, Adenoviridae, European Innovation Council, Herv, Cancer, Venture capital financing, Breast, CMO, RNA, Immunotherapy, Doctor of Philosophy, HERV, Manager, EUR, Koala retrovirus, Novartis, MD, Investment, Immune system, Novo Nordisk Foundation, Drug development, FIH, Growth, Merck, BII, EIC, Seed, MPM, SME, Pharmaceutical industry, Management, Security (finance), EU

The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumors, into clinical development.

Key Points: 
  • The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumors, into clinical development.
  • InProTher has generated robust pre-clinical, proof-of-concept data that demonstrates therapeutic potential for multiple oncology indications including pancreatic, ovarian, breast and prostate cancer.
  • Jordi Naval, Chief Executive Officer of InProTher said: "InProTher is shifting the paradigm in cancer immunotherapy and is at an exciting phase of growth.
  • The Seed round of EUR 6M includes private investors and a convertible loan from EICF.

GeNeuro : Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody

Retrieved on: 
Martedì, Agosto 30, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, Amyotrophic lateral sclerosis, National, COVID-19, NINDS, Technology, National Institute, Herve Damas, Survival, Annals of Neurology, Degenerative disease, Death, Multiple sclerosis, Lists of diseases, CSF, DNA, HERV-K, NIH, Euronext Paris, Patent, National Institute of Neurological Disorders and Stroke, Neurotoxicity, Autoantibody, Transactions of the American Neurological Association, Publication, ENV, American Neurological Association, MS, Cerebrospinal fluid, ALS, Patient, Vaccine, Amyotrophy, HERV, Neurology, Stroke

NINDS is part of the National Institutes of Health (NIH) of the United States.

Key Points: 
  • NINDS is part of the National Institutes of Health (NIH) of the United States.
  • The two publications describe the novel pathogenic mechanism of HERV-K in sporadic ALS and confirm the rationale for the therapeutic relevance of GeNeuro's antibody to neutralize this neurotoxic protein.
  • Annals of Neurology is an official journal of the American Neurological Association.
  • GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France.